ROCHE HOLDING AG

Roche’s KRAS G12C inhibitor tops rivals in NSCLC, driving Swiss shares 4 % higher with 45 % response rate and 18.4 mo OS—boosting precision‑oncology prospects and investor confidence.

Roche’s new drug divarasib beats current KRAS G12C inhibitors in a Phase‑III trial, improving survival in NSCLC while keeping safety unchanged.

Roche Holding AG drives Swiss market momentum with strong index gains, a 12% oncology CAGR, AI‑powered diagnostics, and value‑based pricing that balances growth and patient access.

Roche Holding AG’s modest 21 May 2026 decline reflects broader Swiss market volatility, yet the company’s strong fundamentals, robust R&D pipeline, and proactive reimbursement strategy continue to drive value for shareholders.

Roche Holding AG’s H1 2026 results show modest NAV growth but lag the MSCI Europe Index, highlighting the impact of tight growth‑stock valuations and concentration risk. The board’s focus on disciplined buy‑backs, quality‑growth investing, and tech‑…

Roche’s breakthroughs in multiplex molecular diagnostics and AI‑driven supply‑chain resilience boost 12.7 % CAGR growth, cutting costs, speeding results, and driving superior reimbursement and margins.

Roche Holding AG’s 2026 AGM highlights Swiss R&D focus, new equity structure, dividend boost, and a clear plan to tackle patent cliffs while targeting M&A to stay pharma‑market‑leading.

Roche’s market dip amid geopolitical tension masks strong clinical progress—phase‑III ALLEGORY shows 46% SLE remission, while phase‑II Petrelintide cuts BMI by 2.8 kg/m².

Roche’s latest regulatory moves—dropping Enspryng and winning FDA NDA acceptance for a new breast‑cancer drug and a giredestrant combo—signal a sharp focus on high‑impact oncology therapies and a promise of improved outcomes for hormone‑positive bre…

Roche’s FDA‑approved breast‑cancer therapy RO‑101 shows a 12.6‑month median PFS, while its ER‑OAR+everolimus combo promises 9.2‑month PFS and higher response rates—2026‑decision outlook revealed.